Cyrus V. Hedvat - Concepedia

Author

Cyrus V. Hedvat

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

C Hedvat, C V Hedvat, C. Hedvat, C.V. Hedvat, Cyrus Hedvat, Cyrus V Hedvat, Cyrus V. Hedvat, Hedvat, Cyrus

124

Publications

13.1K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Kettering University Harvard University The University of Texas MD Anderson Cancer Center

About

Cyrus V. Hedvat is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	30	6.3K
2	Health Sciences	3	3	338
3	Engineering	2	2	2.1K
4	Natural Sciences	2	2	104
5	Biochemistry	1	1	2K

Cyrus V. Hedvat

Publications

12.9K

Citations

H-Index

Page 1

	Year	Citations
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing Garrett M. Frampton, Alex Fichtenholtz, Geoff Otto, Nature Biotechnology Dna SequencingClinical CancerEngineeringTumor HeterogeneityMedicine	2013	2.1K
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia Renier J. Brentjens, Marco L. Davila, Isabelle Rivière, Science Translational Medicine	2013	2.1K
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate Patrick S. Ward, Jay Patel, David R. Wise, Cancer Cell Somatic VariantBiochemistryMedicineGeneticsInherited Metabolic Disease	2010	2K
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Omar Abdel‐Wahab, Ann Mullally, Cyrus V. Hedvat, Blood	2009	713
p63 expression profiles in human normal and tumor tissues. Charles J. Di Como, Marshall Urist, Irina Babayan, PubMed	2002	521
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma Richard D. Carvajal, Jeffrey A. Sosman, J. Fernando Quevedo, JAMA	2014	421
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation Ekaterina Doubrovina, Banu Oflaz-Sozmen, Susan E. Prockop, Blood	2011	416
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer Kevin Kalinsky, Lindsay M. Jacks, Adriana Heguy, Clinical Cancer Research	2009	412
Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias Omar Abdel‐Wahab, Taghi Manshouri, Jay Patel, Cancer Research	2010	317
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation Janis M. Taube, Güray Aktürk, Michael Angelo, Journal for ImmunoTherapy of Cancer	2020	275

Page 1